Annual Cash & Cash Equivalents
$35.44 M
+$24.09 M+212.13%
31 December 2023
Summary:
Lineage Cell Therapeutics annual cash & cash equivalents is currently $35.44 million, with the most recent change of +$24.09 million (+212.13%) on 31 December 2023. During the last 3 years, it has risen by +$2.86 million (+8.77%). LCTX annual cash & cash equivalents is now -36.42% below its all-time high of $55.74 million, reached on 31 December 2021.LCTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$27.75 M
-$1.87 M-6.32%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly cash and cash equivalents is currently $27.75 million, with the most recent change of -$1.87 million (-6.32%) on 30 September 2024. Over the past year, it has dropped by -$3.72 million (-11.83%). LCTX quarterly cash and cash equivalents is now -64.45% below its all-time high of $78.06 million, reached on 31 March 2022.LCTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +212.1% | -11.8% |
| 3 y3 years | +8.8% | -54.4% |
| 5 y5 years | +50.3% | +93.2% |
LCTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -36.4% | +212.1% | -64.5% | +144.4% |
| 5 y | 5 years | -36.4% | +273.2% | -64.5% | +192.2% |
| alltime | all time | -36.4% | >+9999.0% | -64.5% | >+9999.0% |
Lineage Cell Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $27.75 M(-6.3%) |
| June 2024 | - | $29.62 M(-32.0%) |
| Mar 2024 | - | $43.58 M(+23.0%) |
| Dec 2023 | $35.44 M(+212.1%) | $35.44 M(+12.6%) |
| Sept 2023 | - | $31.47 M(-7.1%) |
| June 2023 | - | $33.89 M(+119.3%) |
| Mar 2023 | - | $15.45 M(+36.1%) |
| Dec 2022 | $11.36 M(-79.6%) | $11.36 M(-54.1%) |
| Sept 2022 | - | $24.75 M(-65.1%) |
| June 2022 | - | $70.86 M(-9.2%) |
| Mar 2022 | - | $78.06 M(+40.0%) |
| Dec 2021 | $55.74 M(+71.1%) | $55.74 M(-8.3%) |
| Sept 2021 | - | $60.81 M(-1.9%) |
| June 2021 | - | $62.00 M(+10.3%) |
| Mar 2021 | - | $56.21 M(+72.5%) |
| Dec 2020 | $32.59 M(+243.1%) | $32.59 M(+0.1%) |
| Sept 2020 | - | $32.56 M(+156.9%) |
| June 2020 | - | $12.68 M(+28.9%) |
| Mar 2020 | - | $9.83 M(+3.5%) |
| Dec 2019 | $9.50 M(-59.7%) | $9.50 M(-33.9%) |
| Sept 2019 | - | $14.37 M(+75.0%) |
| June 2019 | - | $8.21 M(-54.4%) |
| Mar 2019 | - | $18.01 M(-23.6%) |
| Dec 2018 | $23.59 M(-36.0%) | $23.59 M(+21.2%) |
| Sept 2018 | - | $19.47 M(-28.4%) |
| June 2018 | - | $27.21 M(-8.8%) |
| Mar 2018 | - | $29.83 M(-19.0%) |
| Dec 2017 | $36.84 M(+66.8%) | $36.84 M(+121.1%) |
| Sept 2017 | - | $16.66 M(+14.5%) |
| June 2017 | - | $14.55 M(-38.9%) |
| Mar 2017 | - | $23.82 M(+7.8%) |
| Dec 2016 | $22.09 M(-47.7%) | $22.09 M(-27.5%) |
| Sept 2016 | - | $30.45 M(+9.9%) |
| June 2016 | - | $27.70 M(+2.1%) |
| Mar 2016 | - | $27.13 M(-35.8%) |
| Dec 2015 | $42.23 M(+43.2%) | $42.23 M(+43.7%) |
| Sept 2015 | - | $29.38 M(-6.6%) |
| June 2015 | - | $31.46 M(+21.8%) |
| Mar 2015 | - | $25.83 M(-12.4%) |
| Dec 2014 | $29.49 M(+436.6%) | $29.49 M(+297.6%) |
| Sept 2014 | - | $7.42 M(-52.8%) |
| June 2014 | - | $15.72 M(+136.8%) |
| Mar 2014 | - | $6.64 M(+20.8%) |
| Dec 2013 | $5.50 M(+26.3%) | $5.50 M(-18.2%) |
| Sept 2013 | - | $6.72 M(-53.0%) |
| June 2013 | - | $14.31 M(+44.6%) |
| Mar 2013 | - | $9.90 M(+127.5%) |
| Dec 2012 | $4.35 M(-80.4%) | $4.35 M(-44.4%) |
| Sept 2012 | - | $7.83 M(-38.1%) |
| June 2012 | - | $12.66 M(-23.2%) |
| Mar 2012 | - | $16.49 M(-25.8%) |
| Dec 2011 | $22.21 M(-33.3%) | $22.21 M(-15.3%) |
| Sept 2011 | - | $26.23 M(-4.2%) |
| June 2011 | - | $27.38 M(-9.1%) |
| Mar 2011 | - | $30.14 M(-9.6%) |
| Dec 2010 | $33.32 M(+173.4%) | $33.32 M(+31.1%) |
| Sept 2010 | - | $25.42 M(+40.8%) |
| June 2010 | - | $18.06 M(+61.6%) |
| Mar 2010 | - | $11.17 M(-8.3%) |
| Dec 2009 | $12.19 M(>+9900.0%) | $12.19 M(+53.5%) |
| Sept 2009 | - | $7.94 M(+69.3%) |
| June 2009 | - | $4.69 M(+767.3%) |
| Mar 2009 | - | $541.10 K(+4299.2%) |
| Dec 2008 | $12.30 K | $12.30 K(-76.4%) |
| Sept 2008 | - | $52.10 K(-69.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2008 | - | $172.50 K(-43.9%) |
| Mar 2008 | - | $307.50 K(+3136.8%) |
| Dec 2007 | $9500.00(-98.3%) | $9500.00(-31.2%) |
| Sept 2007 | - | $13.80 K(-89.2%) |
| June 2007 | - | $127.20 K(-54.1%) |
| Mar 2007 | - | $277.30 K(-50.6%) |
| Dec 2006 | $561.00 K(-69.4%) | $561.00 K(-25.8%) |
| Sept 2006 | - | $755.60 K(-24.4%) |
| June 2006 | - | $999.40 K(-8.2%) |
| Mar 2006 | - | $1.09 M(-40.6%) |
| Dec 2005 | $1.83 M(+33.8%) | $1.83 M(+944.3%) |
| Sept 2005 | - | $175.60 K(-70.2%) |
| June 2005 | - | $588.50 K(-17.3%) |
| Mar 2005 | - | $711.80 K(-48.1%) |
| Dec 2004 | $1.37 M(+91.1%) | $1.37 M(-12.6%) |
| Sept 2004 | - | $1.57 M(-10.4%) |
| June 2004 | - | $1.75 M(-17.4%) |
| Mar 2004 | - | $2.12 M(+195.6%) |
| Dec 2003 | $717.20 K(-44.2%) | $717.20 K(-39.3%) |
| Sept 2003 | - | $1.18 M(+81.7%) |
| June 2003 | - | $650.40 K(-10.1%) |
| Mar 2003 | - | $723.50 K(-43.7%) |
| Dec 2002 | $1.28 M(-22.3%) | $1.28 M(-29.8%) |
| Sept 2002 | - | $1.83 M(+264.9%) |
| June 2002 | - | $501.30 K(-49.2%) |
| Mar 2002 | - | $987.50 K(-40.2%) |
| Dec 2001 | $1.65 M(+25.4%) | $1.65 M(-14.7%) |
| Sept 2001 | - | $1.94 M(+903.7%) |
| June 2001 | - | $193.00 K(-40.0%) |
| Mar 2001 | - | $321.50 K(-75.6%) |
| Dec 2000 | $1.32 M(-75.1%) | $1.32 M(-34.8%) |
| Sept 2000 | - | $2.02 M(-16.7%) |
| June 2000 | - | $2.43 M(-34.2%) |
| Mar 2000 | - | $3.69 M(-30.3%) |
| Dec 1999 | $5.29 M(+120.5%) | $5.29 M(-19.8%) |
| Sept 1999 | - | $6.60 M(-8.3%) |
| June 1999 | - | $7.20 M(-16.3%) |
| Mar 1999 | - | $8.60 M(+160.6%) |
| Dec 1998 | $2.40 M(-41.5%) | - |
| Sept 1998 | - | $3.30 M(-19.5%) |
| June 1998 | - | $4.10 M(-19.6%) |
| June 1998 | $4.10 M(-47.4%) | - |
| Mar 1998 | - | $5.10 M(-19.0%) |
| Dec 1997 | - | $6.30 M(-14.9%) |
| Sept 1997 | - | $7.40 M(-5.1%) |
| June 1997 | $7.80 M(+225.0%) | $7.80 M(+6.8%) |
| Mar 1997 | - | $7.30 M(+305.6%) |
| Dec 1996 | - | $1.80 M(-10.0%) |
| Sept 1996 | - | $2.00 M(-16.7%) |
| June 1996 | $2.40 M(-29.4%) | $2.40 M(-17.2%) |
| Sept 1995 | - | $2.90 M(-14.7%) |
| June 1995 | $3.40 M(+385.7%) | $3.40 M(+277.8%) |
| Mar 1995 | - | $900.00 K(-40.0%) |
| Dec 1994 | - | $1.50 M(+650.0%) |
| Sept 1994 | - | $200.00 K(-71.4%) |
| June 1994 | $700.00 K(-53.3%) | $700.00 K(-46.2%) |
| Mar 1994 | - | $1.30 M(-51.9%) |
| Dec 1993 | - | $2.70 M(+145.5%) |
| Sept 1993 | - | $1.10 M(-26.7%) |
| June 1993 | $1.50 M(-68.8%) | $1.50 M(-60.5%) |
| Mar 1993 | - | $3.80 M(-7.3%) |
| Dec 1992 | - | $4.10 M(-6.8%) |
| Sept 1992 | - | $4.40 M(-8.3%) |
| June 1992 | $4.80 M | $4.80 M(-5.9%) |
| Mar 1992 | - | $5.10 M |
FAQ
- What is Lineage Cell Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual cash & cash equivalents year-on-year change?
- What is Lineage Cell Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Lineage Cell Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of LCTX is $35.44 M
What is the all time high annual cash & cash equivalents for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual cash & cash equivalents is $55.74 M
What is Lineage Cell Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, LCTX annual cash & cash equivalents has changed by +$24.09 M (+212.13%)
What is Lineage Cell Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LCTX is $27.75 M
What is the all time high quarterly cash and cash equivalents for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly cash and cash equivalents is $78.06 M
What is Lineage Cell Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, LCTX quarterly cash and cash equivalents has changed by -$3.72 M (-11.83%)